[Skip to Content]
[Skip to Content Landing]
June 2004

Do Antihistone Autoantibodies Reflect Disease Activity in Linear Scleroderma?

Author Affiliations

Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004

Arch Dermatol. 2004;140(6):759-760. doi:10.1001/archderm.140.6.759

Antihistone autoantibodies (AHAs) were studied by Sato et al,13 who found a higher prevalence in the generalized forms of localized scleroderma than in the less extensive forms. They suggested that AHAs correlate with the extent of disease. The value of assessing AHAs and their correlation with disease activity longitudinally was not determined. We describe 4 patients with linear scleroderma who had positive AHA titers and who were treated with hydroxychloroquine sulfate. They were followed up longitudinally for as long as 4 years. Clinical response was assessed on a 4-point scale (Figure 1). The clinical end point of treatment was softening of induration and resolution of inflammation with or without postinflammatory hyperpigmentation. The AHA titers were measured as the total IgG concentration (H1, H2, H2B, H3, and H4) with an enzyme-linked immunosorbent assay (Quanta Lite Histone; INOVA Diagnostics Inc, San Diego, Calif).

First Page Preview View Large
First page PDF preview
First page PDF preview